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Abstract
Background: Arthrobacter-like organisms, including Pseudoclavibacter organisms, have rarely been documented as
being responsible for infection in humans.
Case presentation: An 81-year-old French man developed a subcutaneous infection despite antibiotic treatment
combining clindamycin and metronidazole for chronic wound infection. A skin biopsy showed numerous
polymorphonuclear cells and no bacteria, but a subcutaneous swab yielded numerous polymorphonuclear cells, a
few Gram-positive cocci, Gram-negative cocci, and Gram-positive rods. The Gram-positive rod sequence exhibited
99% sequence similarity with uncultured Pseudoclavibacter sp. [GenBank:EF419350] and 99% sequence similarity
with uncultured Pseudoclavibacter sp. [GenBank:EF419347]. The genetic data and unique peptide profile of this
Pseudoclavibacter-like isolate, determined by matrix-assisted laser desorption ionization-time of flight mass
spectrometry, underscored its uniqueness.
Conclusions: Pseudoclavibacter-like organisms are identifiable in cutaneous and subcutaneous infections in
humans.
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Background
Pseudoclavibacter is an emerging bacterial genus created
a few years ago to accommodate environmental Brevi-
bacterium organisms [1]. Indeed, Arthrobacter-like bac-
teria have rarely been isolated in patients, and a
Pseudoclavibacter organism has been reported to be iso-
lated only once, from an aortic valve of a 74-year-old
man [2].
Case presentation
An 81-year-old French man was admitted to our hospi-
tal for erysipelas of the right leg. The patient had sud-
denly developed this infection despite antibiotic
treatment combining clindamycin and metronidazole for
a chronic wound infection of the same leg with previous
documentation of clindamycin-susceptible Staphylococ-
cus aureus, Klebsiella oxytoca, Serratia marcescens,a n d
Corynebacterium spp., but no anaerobe. His leukocyte
count was 10.32 g/L with 72% polymorphonuclear cells,
18% lymphocytes, and 8% monocytes. Inflammatory syn-
drome was apparent with a C-reactive protein level of
119 mmol/L and a fibrinogen level of 8.6 g/L. Antibo-
dies against streptolysin O and streptococcal DNase
were not detectable in the patient’s serum. Direct micro-
scopic examination of a skin biopsy showed numerous
polymorphonuclear cells and no bacteria. Culture
remained sterile after a five-day inoculation on Colum-
bia agar with 5% sheep blood (bioMérieux, Marcy-
l’Etoile, France), Chocolate agar with PolyViteX agar
(bioMérieux) and MacConkey agar (bioMérieux) at 37°C
in 5% CO2. Three days later a subcutaneous swab
yielded numerous polymorphonuclear cells, and semi-
quantitative direct examination indicated an average of
15 to 30 organisms per microscopic field composed of
an equal proportion of Gram-positive cocci, Gram-nega-
tive cocci, and Gram-positive rods. Culture under the
same conditions described above yielded small, gray
colonies after 48-hour inoculation on Columbia agar
with 5% sheep blood. The Gram-positive rod was oxi-
dase-negative and catalase-positive. Inoculation of an
API Coryne system identification strip (bioMérieux),
performed twice, yielded no reaction and thus no
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this specimen. Antibiotic susceptibility assessed on
Mueller-Hinton agar (bioMérieux) using the disc
method (Mast Diagnostics, Amiens, France) and break
points as previously reported [3] yielded susceptibility to
amoxicillin (minimum inhibitory concentration (MIC) ≤
2 mg/L), rifampin (MIC ≤ 4 mg/L), doxycycline (MIC ≤
4 mg/L), and vancomycin (MIC ≤ 4m g / L )a n dr e s i s -
tance to co-trimoxazole, clindamycin, and metronida-
zole. The latter three antibiotics yielded no growth
inhibition zone. To identify the isolate, we amplified (by
polymerase chain reaction) and sequenced 1431 bases of
the 16S rRNA gene [GenBank:FJ375951] [4]. This
sequence exhibited 99% sequence similarity with uncul-
tured Pseudoclavibacter sp. [GenBank:EF419350] and
99% sequence similarity with uncultured Pseudoclavi-
bacter sp. [GenBank:EF419347]. The third hit exhibited
only 97% sequence similarity with Zimmermannella
bifida [GenBank:AB012589]. The peptide profile of the
isolate was determined by matrix-assisted laser deso-
rption ionization-time of flight (MALDI-TOF) mass
spectrometry as previously described [5] (Figure 1).
MALDI-TOF-based identification was achieved by com-
paring the isolate profile with the 3438 bacterial profiles
deposited in the MALDI BioTyper database (Bruker
Corp. Bremen, Germany), which includes 56 Arthrobac-
ter,1 7Brevibacterium,t h r e ePseudoclavibacter,a n dn o
Zimmermannella organism profiles (as of June 2010).
The isolate was not identified with any of the species in
the database, with the best identification score being
1.326 with Corynebacterium afermentans.T h ei s o l a t e
has been deposited in the Collection de Souches de
l’Unité des Rickettsies, Marseilles, France (CSUR P29).
The clinical evolution was favorable under antibiotic
treatment combining intravenous imipenem and vanco-
mycin. Oral treatment with amoxicillin/clavulanate
replaced intravenous antibiotics on day six.
Identification of the isolate was made possible only
after 16S rRNA gene sequence analysis, as the isolate
was not reactive on identification strips and did not
exhibit any identifying phenotype. The 16S rRNA gene
sequence comparison indicated that this isolate is repre-
sentative of a previously uncultured organism. This case
illustrates a new paradigm in using 16S rRNA gene
sequence-based identification of organisms in clinical
microbiology laboratories. Indeed, most of the emerging
bacteria have been described previously on the basis of
an original bacterial isolate exhibiting a 16S rRNA gene
sequence with < 98.7% sequence similarity with any
other sequence [4,6,7]. In our case report, however, the
16S rRNA gene sequence was already available in Gen-
Bank before we recovered the isolate. Indeed, extensive
genomic and metagenomic explorations of complex
environmental and mucosa-associated flora yielded a
tremendous amount of the original 16S rRNA gene
sequence from as-yet-uncultured organisms [8,9]. In our
case report, isolation of an organism exhibiting a 16S
rRNA gene sequence identical to that of a previously
uncultured organism underscores the uniqueness of this
isolate.
Figure 1 Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass-spectrometry peptide profile of a
Pseudoclavibacter-like organism. This profile could be used as a reference for rapid identification of this bacterial species.
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In the case of our patient, the Pseudoclavibacter-like
organism was most probably involved in his clinical
infection, since this Gram-positive rod was observed in
the presence of pus during the direct examination of a
subcutaneous specimen. It grew in pure culture from a
patient who was taking two antibiotics to which the
Pseudoclavibacter-like organism was found to be resis-
tant, thus supporting the hypothesis that growth of the
Pseudoclavibacter-like organism was indeed selected by
the antibiotic treatment. Also, Pseudoclavibacter sp. and
other Arthrobacter-like organisms have never been
reported as potential contaminants of culture, and Pseu-
doclavibacter spp. have not been isolated in our labora-
tory, with the exception of this patient. The 16S rRNA
gene sequence of identical Pseudoclavibacter-like organ-
isms was found in the diseased skin of patients with
psoriasis before we obtained the first isolate [10]. This
fact and the data presented in this case report suggest
that Pseudoclavibacter-like organisms are organisms
involved in skin diseases. Pseudoclavibacter-like organ-
isms are bacterial organisms identifiable in cutaneous
a n ds u b c u t a n e o u si n f e c t i o n si nh u m a n so nt h eb a s i so f
au n i q u ep e p t i d ep r o f i l eo b t a i n e db yM A L D I - T O Fa n a -
lysis and unique 16S rRNA gene sequencing.
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